← Leaderboards
Theodore G Liou
University Of Utah
$2,244,749
Attributed
$2,244,749
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $380.9K · FY2005–18$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,244,749 · 14
By mechanism
R01$1,363,854 · 1
R21$411,125 · 1
K08$247,860 · 1
M01$221,910 · 11
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisResearch PersonnelSourceChronicUnited States National Institutes Of HealthCystic Fibrosis PatientsResourcesComputer Retrieval Of Information On Scientific Projects DatabaseFundingInstitutionGrantUnited StatesRespiratory PhysiologyCystic Fibrosis Transmembrane Conductance RegulatorPharmaceutical PreparationsLung DiseasesLeadLungInflammationBaseInfectionGenesDiabetes MellitusAntibiotics
Grant awards (20)
Explanatory models of CF Survival, Infection and Intermediate Clinical Outcomes$337,901
R01 · FY2018 · HL · contact PI
Explanatory models of CF Survival, Infection and Intermediate Clinical Outcomes$337,901
R01 · FY2017 · HL · contact PI
Explanatory models of CF Survival, Infection and Intermediate Clinical Outcomes$337,901
R01 · FY2016 · HL · contact PI
Explanatory models of CF Survival, Infection and Intermediate Clinical Outcomes$350,151
R01 · FY2015 · HL · contact PI
Polymicrobial disease and inflammation in cystic fibrosis$186,875
R21 · FY2008 · HL · contact PI
CLINICAL TRIAL: CORRECTION OF STEATORRHEA IN PATIENS WITH CYSTIC FIBROSIS$19,600
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS PATIENTS$3,610
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: DENUFOSOL TETRASODIUM INHALATION SOLUTION IN PATIENTS WITH MILD$946
M01 · FY2008 · RR · contact PI
DIABETES THERAPY IN CYSTIC FIBROSIS SUBJECTS$430
M01 · FY2008 · RR · contact PI
Polymicrobial disease and inflammation in cystic fibrosis$224,250
R21 · FY2007 · HL · contact PI
CORRECTION OF STEATORRHEA IN PATIENS WITH CYSTIC FIBROSIS$124,843
M01 · FY2007 · RR · contact PI
AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS PATIENTS$22,997
M01 · FY2007 · RR · contact PI
DENUFOSOL TETRASODIUM INHALATION SOLUTION IN PATIENTS WITH MILD CYSTIC FIBROSIS$6,024
M01 · FY2007 · RR · contact PI
DIABETES THERAPY IN CYSTIC FIBROSIS SUBJECTS$2,738
M01 · FY2007 · RR · contact PI
AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS PATIENTS$16,655
M01 · FY2006 · RR · contact PI
CYSTIC FIBROSIS PATIENTS WITH LUNG DISEASE DUE TO P AERUGINOSA INFECTION$20,135
M01 · FY2005 · RR
Cystic fibrosis patients with lung disease$2,185
M01 · FY2004 · RR
Diabetes therapy in CF subjects$1,747
M01 · FY2004 · RR
NON-CONTACT BASED INTERCELLULAR COMMUNICATION ON NEUTROP$123,930
K08 · FY2001 · HL
NON-CONTACT BASED INTERCELLULAR COMMUNICATION ON NEUTROP$123,930
K08 · FY2000 · HL